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Intratumoral heterogeneity contributes to cancer drug resistance, but the underlying mechanisms
are not understood. Single-cell analyses of patient-derived models and clinical samples from
glioblastoma patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) demonstrate that tumor cells reversibly up-regulate or suppress mutant EGFR
expression, conferring distinct cellular phenotypes to reach an optimal equilibrium for growth.
Resistance to EGFR TKIs is shown to occur by elimination of mutant EGFR from
extrachromosomal DNA. After drug withdrawal, reemergence of clonal EGFR mutations on
extrachromosomal DNA follows. These results indicate a highly specific, dynamic, and adaptive
route by which cancers can evade therapies that target oncogenes maintained on
extrachromosomal DNA.
The majority of targeted therapies have not produced substantial survival benefits for most
cancer patients (1, 2). A variety of resistance mechanisms have been described, including
incomplete target suppression, second-site mutations, and activation of alternative kinases to
maintain signal flux to downstream effector pathways (1–3). Thus, most efforts are now
aimed at developing better drugs or better drug combinations to more fully suppress the
target oncogenes and their downstream signals. Changes in the cellular composition of
tumors, particularly in response to targeted treatment, could facilitate such a resistance
mechanism and thereby dictate patient response.
In glioblastoma (GBM), the most common malignant primary brain cancer of adults, the
epidermal growth factor receptor (EGFR) is frequently mutated, commonly giving rise to the
constitutively active oncogenic variant EGFRvIII (4, 5). EGFRvIII potently accelerates
tumor growth by cell-autonomous and intercellular signaling mechanisms (6), but it also
makes tumor cells that express it more sensitive to EGFR tyrosine kinase inhibitors (TKIs)
(7, 8). In clinical GBM samples, the level of EGFRvIII protein expression varies widely
among cells within the tumor mass (6, 9–15). The potential contribution of heterogeneous
EGFRvIII expression to EGFR TKI resistance in GBM (16) is not understood.
To determine whether EGFRvIII heterogeneity contributes to EGFR TKI resistance, single-
cell analyses of a patient-derived EGFRvIII-expressing xenograft model (GBM39) (17)
were performed. GBM39 cells stably express firefly luciferase (ff-LUC), enabling definitive
tumor cell identification (fig. S1A). Quantitative microfluidic image cytometry (MIC) (18)
demonstrated detectable levels of EGFRvIII protein in 60% (±5%) of tumor cells (fig. S1B).
The EGFRvIII-expressing tumor cells (EGFRvIIIHigh) demonstrated increased
phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin (PI3K-Akt-mTOR)
signaling (Fig. 1A and fig. S2), elevation in tumor cell proliferation by a factor of 4 (Fig. 1B
and fig. S2), a lower basal apoptotic rate by a factor of 15 (Fig. 1C and fig. S2), and
increased glucose uptake (Fig. 1D) relative to the GBM cells lacking detectable EGFRvIII
protein (EGFRvIIILow) (Fig. 1, D and E). Further, the EGFRvIIIHigh tumor cells showed
enhanced cell death in response to the EGFR TKI erlotinib (Fig. 1F).
To determine the effect of an EGFR TKI on EGFRvIII population dynamics, mice bearing
tumors were treated daily with oral erlotinib (150 mg per kg of weight). Erlotinib treatment
initially caused 80% tumor shrinkage (response) (blue line in Fig. 1G), shifting the
composition of tumors from being predominantly EGFRvIIIHigh to predominantly
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EGFRvIIILow tumor cells (Fig. 1H and fig. S3). This shift in the EGFRvIII population
dynamics was maintained, even after tumors developed resistance to continued erlotinib
treatment (resistant) [Fig. 1G (red line) and H, and fig. S3], and was also detected in another
patient-derived ex vivo neurosphere culture, HK296 (fig. S4). Most important, in tumor
tissue from GBM patients treated for 7 to 10 days with the EGFR/HER2 inhibitor lapatinib,
the relative fraction of EGFRvIIIHigh tumor cells dramatically declined relative to each
patient's pretreatment sample (Fig. 1, I and J). Of note, this analysis was confined to patients
whose posttreatment tumor tissue showed reduced EGFR phosphorylation relative to the
pretreatment sample. We did not detect any decrease in EGFRvIII level in the two available
GBMs in which no decrease in phospho-EGFR was seen after lapatinib treatment.
Unexpectedly, EGFRvIIIHigh/EGFRvIIILow GBM subpopulations sorted by fluorescence-
activated cell sorting (FACS) proved to be equally tumorigenic, giving rise to heterogeneous
tumors (Fig. 2, A and B). Seeds containing ~200, 2000, or 20,000 cells of FACS-sorted
EGFRvIIIHigh/EGFRvIIILow subpopulations generated subcutaneous tumors of similar size,
containing the same ratio of EGFRvIIIHigh/EGFRvIIILow cells as the original tumor (Fig.
2C). FACs-sorted pure populations of EGFRvIIIHigh and EGFRvIIILow GBM cells plated at
2 to 5 cells per well, or even as single cells per well, gave rise to colonies containing a
similar ratio of EGFRvIIIHigh/EGFRvIIILow cells (Fig. 2, D to F). These findings are
consistent with a stochastic state transition model, in which distinct tumor subpopulations
regenerate the phenotypic equilibrium characteristic of the original tumor (19). Erlotinib
treatment completely suppressed this state transition and maintained the population in an
EGFRvIIILow state, and it continued to do so long after any tumor cell death was observed
(fig. S5).
To determine the mechanism by which GBM cells modulate EGFRvIII protein levels during
erlotinib resistance, we generated a reversible EGFR TKI resistance model by continuous
treatment of GBM cells with erlotinib in GBM39 cells in neurosphere culture, followed by
drug withdrawal (Fig. 3, A to C), and examined the level, sequence, and subnuclear
localization of EGFRvIII DNA. EGFRvIII arises from an in-frame genomic deletion of
exons 2 to 7 of the EGFR gene and has been thought to reside primarily on small circular
extrachromosomal fragments of DNA called double-minute (DM) chromosomes (20–22).
Fluorescent in situ hybridization (FISH) of naïve (n = 15 metaphases), erlotinib-resistant (n
= 15 metaphases), and drug-removed (n = 10 metaphases) GBM39 metaphase cells with
EGFR and centromere 7–specific DNA probes revealed abundant EGFR+ extrachromosomal
DNA in naïve and drug-removed tumor cells and a complete loss of these EGFR+
extrachromosomal DNA elements in erlotinib-resistant GBM cells (Fig. 3D). No changes in
chromosomal EGFR copy number were detected between naïve, erlotinib-resistant, or drug-
removed GBM cells. The overall FISH signal patterns were confirmed by analysis of more
than 100 interphase nuclei from each of the three conditions (fig. S7). The loss of EGFR+
extrachromosomal DNA in erlotinib resistance was specific, because these cells still
contained abundant extrachromosomal DNA elements (fig. S6), including MDM2+ DMs,
which were identified by FISH and polymerase chain reaction (PCR)–Southern blot
analysis. The MDM2+ DM copy number rose with erlotinib treatment and remained
elevated, even after drug withdrawal (fig. S8). In each erlotinib-resistant metaphase or
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interphase cell, a single marker chromosome made up of homogeneous staining regions
(HSRs) positive for EGFR, but lacking the chromosome 7–specific centromere sequences,
was detected. Similar HSR-like EGFR+ marker chromosomes were detected in naïve and
drug-removed GBM metaphases, raising the possibility that these bodies may serve as a
latent reservoir for EGFRvIII in erlotinib-resistant GBM cells (Fig. 3D and fig. S9).
To confirm that the EGFR+ extrachromosomal elements were EGFRvIII, we performed
Southern blot, PCR, and sequencing analyses of low-molecular-weight extrachromosomal
DNA (Fig. 3, E to I). A 4.1-kb band in BamH1-digested low-molecular-weight DNA
indicative of EGFRvIII was detected in naïve and drug-removed GBM39 cells but not
erlotinib-resistant cells (Fig. 3, E and F). The intronic breakpoints that give rise to the
EGFRvIII deletion are not consistent, varying between individuals (23). Therefore, we
designed primers mapping at each of the 17 BamH1 restriction sites spanning the region of
interest. PCR and Southern blot analyses identified a genomic deletion confirmed to be
EGFRvIII by sequencing of cloned fragments (fig. S10 and Fig. 3, E to I). We identified the
intronic breakpoints giving rise to EGFRvIII in two additional patient-derived GBM ex vivo
neurosphere cultures (GBM6 and HK296) (fig. S10) (24, 25) and measured
extrachromosomal EGFRvIII DNA copy number in naïve and erlotinib-resistant cells,
including after drug withdrawal, by a quantitative PCR assay. Consistent with the effect of
erlotinib in GBM39 cells, continuous EGFR TKI treatment caused almost complete loss of
extrachromosomal EGFRvIII DNA and erlotinib resistance (Fig. 4A and fig. S11).
Remarkably, cessation of erlotinib treatment for as little as 72 hours in GBM6 and HK296
markedly increased extrachromosomal EGFRvIII DNA and resensitized tumor cells to
erlotinib-induced cell death (fig. S11).
The availability of two pairs of matched formalin-fixed, paraffin-embedded tissue sections
from patients pre- and post-lapatinib treatment (patients 2 and 3 from Fig. 1, I and J) enabled
us to perform FISH using probes for EGFR (which recognizes EGFRvIII) and centromere 7.
In both patients, a nearly 80% reduction in EGFR FISH-positive signals after lapatinib
treatment was detected (Fig. 4B), thus indicating the clinical relevance of loss of
extrachromosomal EGFRvIII DNA as an EGFR TKI resistance mechanism. In this cohort of
patients, intratumoral lapatinib levels sufficient to cause tumor cell death (2000 to 3000 nM)
were not achieved in the tumor samples (7). However, 1500 nM of lapatinib, an intratumoral
level observed in at least some of these patients, was sufficient to cause highly significant
reduction of extrachromosomal EGFRvIII DNA in GBM39, GBM6, and HK296
neurospheres in culture (fig. S12), suggesting that the significant reduction seen in patients 2
and 3 was a consequence of lapatinib treatment.
Analysis of an additional four matched sets of EGFRvIII-positive tumor tissue from GBM
patients before and after treatment with conventional therapy (temozolomide and radiation)
showed no detectable difference in extrachromosomal EGFR FISH-positive DNA levels
(Fig. 4C). Taken together, these results indicate that loss of extrachromosomal EGFRvIII
DNA is a general and clinically relevant EGFR TKI resistance mechanism in GBM.
It is unusual for EGFRvIII to be homogeneously expressed in a tumor, despite the selective
growth advantage conferred to individual GBM cells (Fig. 1, B, C, E, and F). EGFRvIII
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possibly imposes a cost to tumor cells, potentially by increasing nutrient requirements (Fig.
1D). Notably, the EGFR TKI resistance mechanism identified here is entirely distinct from
the mechanism by which GBMs maintain EGFRvIII heterogeneity in the absence of
treatment. Extrachromosomal EGFRvIII DNA copy number remains elevated in the
treatment-naïve EGFRvIIILow cells (fig. S13), consistent with an epigenetic regulatory
mechanism of EGFRvIII heterogeneity (15). Taken together, these results highlight the
exquisite specificity of reversible loss of extrachromosomal EGFRvIII DNA as a GBM
EGFRTKI resistance mechanism. EGFRvIIIHigh GBMs display enhanced apoptotic
sensitivity to EGFR TKIs (Fig. 1F). However, our data suggest that EGFR TKI resistance
may not be mediated entirely by selection for a subpopulation of tumor cells lacking
extrachromosomal EGFRvIII DNA but may also involve rapid single-step elimination, as
has been described for loss of the DHFR gene on double minutes in the absence of
methotrexate (26, 27) and the loss of MYCC or MYCN from double minutes in the presence
of hydroxyurea (28). These independent and complementary mechanisms of EGFRvIII
regulation, coupled to intercellular signaling between EGFRvIIIHigh/EGFRvIIILow tumor
cells (6), enable GBMs to achieve an EGFRvIIIHigh/EGFRvIIILow ratio that is optimal for
growth and survival, including in response to EGFR TKI therapy. Future work is needed to
examine the compensatory mechanisms that enable GBM cells lacking EGFRvIII
extrachromosomal DNA to continue to proliferate during EGFRTKI treatment, including the
potential role of extrachromosomal MDM2 amplification, and possible changes along the
spectrum of epithelial mesenchymal transition, including irreversible up-regulation of
ZEB-1 (fig. S14), which recently has been shown to promote plasticity and tumorigenicty of
breast cancer cells (29).
Resistance to targeted therapies is a nearly universal clinical challenge for cancer patients (1,
3). Daily dosing with the EGFR TKIs is not optimal because it is hard to achieve sufficient
levels of intratumoral EGFR inhibition (7). Pulsatile intermittent treatment with much higher
doses of an EGFR TKI could potentially lead to better target inhibition and even possibly
less toxicity relative to continuous dosing. In other cancers, a “drug holiday” can resensitize
tumors to targeted therapy (30). The data presented here provide a conceptual mechanistic
rationale for pulsatile intermittent EGFR TKI dosing in GBM to achieve better target
inhibition while permitting tumors to regain drug sensitivity as extrachromosomal EGFRvIII
DNA levels rapidly rise between treatments (fig. S11). These results provide an unexpected
twist showing that loss of EGFRvIII extrachromosomal DNA promotes resistance, in
contrast to the current paradigm of drug resistance through increased levels of
extrachromosomal DNA carrying drug resistance genes (31, 32). These results also highlight
the diversity of mechanisms by which extrachromosomal DNA can promote resistance to
targeted cancer therapies. A number of other oncogenes have been identified on
extrachromosomal DNA (33), potentially enabling them to respond rapidly to targeted drug
treatment (34). It is possible that resistance in other tumor types in which the main oncogene
is extrachromosomal may be similarly mediated by loss of the oncogene on
extrachromosomal DNA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Nathanson et al. Page 5
Science. Author manuscript; available in PMC 2015 January 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Acknowledgments
This work was supported by the Ben and Catherine Ivy Foundation Fund (P.S.M., J.R.H., and T.F.C.); by National
Institutes of Health (NIH) grants NS73831 (P.S.M.), U54 CA151819 (P.S.M. and J.R.H., principal investigator),
P01-CA95616 (W.K.C. and F.B.F.), R01-NS080939 (F.B.F.), and NINDS R01 NS052563 (H.I.K.); and by the
Ziering Family Foundation in memory of Sigi Ziering (T.F.C. and P.S.M.), the Art of the Brain Fund (T.F.C.), the
James S. McDonnell Foundation (to F.B.F.), the European Commission PIOF-GA-2010-271819 (B.G.), Ruth L.
Kirschstein Institutional National Research Service Award T32 CA009056 (D.A.N.), and the UCLA Scholars in
Oncologic Molecular Imaging (SOMI) Program (D.A.N.). W.K.C. is a Fellow of the National Foundation for
Cancer Research. We thank R. Kolodner for careful reading of the manuscript and helpful suggestions. We also
thank W. Yong and the UCLA Brain Tumor Translational Resource.
References and Notes
1. Vogelstein B, et al. Science. 2013; 339:1546–1558. [PubMed: 23539594]
2. Garraway LA, Jänne PA. Cancer Discov. 2012; 2:214–226. [PubMed: 22585993]
3. Glickman MS, Sawyers CL. Cell. 2012; 148:1089–1098. [PubMed: 22424221]
4. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Cancer Res. 2011; 71:4055–4060. [PubMed:
21628493]
5. Brennan CW, et al. Cell. 2013; 155:462–477. [PubMed: 24120142]
6. Inda MM, et al. Genes Dev. 2010; 24:1731–1745. [PubMed: 20713517]
7. Vivanco I, et al. Cancer Discov. 2012; 2:458–471. [PubMed: 22588883]
8. Mellinghoff IK, et al. N. Engl. J. Med. 2005; 353:2012–2024. [PubMed: 16282176]
9. Humphrey PA, et al. Proc. Natl. Acad. Sci. U.S.A. 1990; 87:4207–4211. [PubMed: 1693434]
10. Kurpad SN, et al. Glia. 1995; 15:244–256. [PubMed: 8586461]
11. Aldape KD, et al. J. Neuropathol. Exp. Neurol. 2004; 63:700–707. [PubMed: 15290895]
12. Nishikawa R, et al. Brain Tumor Pathol. 2004; 21:53–56. [PubMed: 15700833]
13. Heimberger AB, et al. Clin. Cancer Res. 2005; 11:1462–1466. [PubMed: 15746047]
14. Jeuken J, et al. Brain Pathol. 2009; 19:661–671. [PubMed: 19744038]
15. Del Vecchio CA, et al. Oncogene. 2013; 32:2670–2681. [PubMed: 22797070]
16. Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R. Clin. Cancer Res. 2008; 14:957–960.
[PubMed: 18281526]
17. Giannini C, et al. Neuro-oncol. 2005; 7:164–176. [PubMed: 15831234]
18. Sun J, et al. Cancer Res. 2010; 70:6128–6138. [PubMed: 20631065]
19. Gupta PB, et al. Cell. 2011; 146:633–644. [PubMed: 21854987]
20. Bigner SH, et al. Cancer Res. 1990; 50:8017–8022. [PubMed: 2253244]
21. Vogt N, et al. Proc. Natl. Acad. Sci. U.S.A. 2004; 101:11368–11373. [PubMed: 15269346]
22. Sanborn JZ, et al. Cancer Res. 2013; 73:6036–6045. [PubMed: 23940299]
23. Frederick L, Wang XY, Eley G, James CD. Cancer Res. 2000; 60:1383–1387. [PubMed:
10728703]
24. Sarkaria JN, et al. Mol. Cancer Ther. 2007; 6:1167–1174. [PubMed: 17363510]
25. Hemmati HD, et al. Proc. Natl. Acad. Sci. U.S.A. 2003; 100:15178–15183. [PubMed: 14645703]
26. Haber DA, Schimke RT. Cell. 1981; 26:355–362. [PubMed: 7326744]
27. Kaufman RJ, Brown PC, Schimke RT. Mol. Cell. Biol. 1981; 1:1084–1093. [PubMed: 7346713]
28. Von Hoff DD, et al. Proc. Natl. Acad. Sci. U.S.A. 1992; 89:8165–8169. [PubMed: 1518843]
29. Chaffer CL, et al. Cell. 2013; 154:61–74. [PubMed: 23827675]
30. Das Thakur M, et al. Nature. 2013; 494:251–255. [PubMed: 23302800]
31. Ercan D, et al. Oncogene. 2010; 29:2346–2356. [PubMed: 20118985]
32. Schimke RT, Kaufman RJ, Alt FW, Kellems RF. Science. 1978; 202:1051–1055. [PubMed:
715457]
33. Benner SE, Wahl GM, Von Hoff DD. Anticancer Drugs. 1991; 2:11–26. [PubMed: 1720337]
34. Shimizu N. Cytogenet. Genome Res. 2009; 124:312–326. [PubMed: 19556783]
Nathanson et al. Page 6
Science. Author manuscript; available in PMC 2015 January 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1. Resistance to EGFR TKIs in preclinical models and GBM patients treated with an EGFR
TKI is associated with a decreasing ratio of EGFRvIIIHigh/EGFRvIIILow tumor cells
(A) FACS-sorted EGFRvIIIHigh and EGFRvIIILow cells obtained from GBM39 differ in
their PI3K-Akt-mTOR activity as determined by immunoblotting. (B) Immunofluorescence
(IF) for EGFRvIII and Ki-67 on isolated GBM39 tumor cells shows differences in basal
proliferative rate between EGFRvIIIHigh and EGFRvIIILow tumor cells. *P < 0.005. (C)
Terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick end
labeling (TUNEL) stain and EGFRvIII IF indicate a higher basal apoptosis in EGFRvIIILow
tumor cells. *P < 0.005. (D and E) Radiopharmaceutical imaging chip analysis of 18F-
fluorodeoxyglucose from FACS-sorted EGFRvIIIHigh and EGFRvIIILow cells indicates
higher glucose uptake in EGFRvIIIHigh cells. **P < 0.05. (F) FACS-sorted EGFRvIIIHigh
and EGFRvIIILow were treated with erlotinib (5 μM) for 24 hours, and cell viability was
determined by trypan blue exclusion assay. **P < 0.05. (G and H) Resistance to erlotinib in
GBM39 xenografts (n = 4 mice per group). During initial response (blue curve) and at the
time of resistance (red curve), there is a relative loss of EGFRvIII-expressing tumor cells. (I
and J) In GBM patients, 10 days of treatment with the EGFR tyrosine kinase inhibitor
lapatinib reduces EGFRvIII expression relative to pretreatment levels. *P < 0.01; **P <
0.0001; #P < 0.001. All values are mean ± SEM. P values were obtained from unpaired t
test.
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Fig. 2. Sorted populations of EGFRvIIIHigh or EGFRvIIILow GBM cells give rise to identical
mixed tumors in vivo
(A) Tumor cells from GBM39 xenografts sorted for EGFRvIII expression and injected into
mice are equally tumorigenic (n = 4 mice per group). The white line indicates 1 inch. (B)
FACS analysis of sorted cells reveals that enriched populations of EGFRvIIIHigh and
EGFRvIIILow tumor cells re-establish mixed populations within 2 weeks. (C) Analysis of
xenograft models deriving from sorted EGFRvIIIHigh and EGFRvIIILow tumor cell
populations from (A) that give rise to tumors with an EGFRvIIIHigh/EGFRvIIILow tumor
cell composition similar to that of initial, untreated GBM39 tumors. Values are mean ±
SEM. (D and E) GBM39 tumor cells sorted for EGFRvIII expression and plated at a single
cell per well and stained for EGFRvIII (red) and 4′,6-diamidino-2-phenylindole (DAPI)
(blue) give rise to heterogeneous colonies. (F) Identical EGFRvIIIHigh/EGFRvIIILow
composition from tumor cells sorted in (D) and plated at 2 to 5 cells per well. Values are
mean ± SEM from n = 5 independent cultures.
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Fig. 3. GBM cells suppress EGFRvIII protein expression on prolonged exposure to erlotinib and
up-regulate it upon drug withdrawal by restoring EGFR+ extrachromosomal DNA elements
(A) Schematic model of reversible EGFR TKI resistance model. GBM39 cells were
maintained in neurosphere culture and were treated continuously with vehicle (naïve) or
erlotinib [5 μM, erlotinib-resistant (ER), 60 days]. Drug was removed from the ER
neurospheres for 30 days [drug-removed (DR)]. (B) Immunoblot of EGFRvIII levels for
naïve, ER, and DR cells. (C) MIC chip quantification of the ratio of EGFRvIIIHigh and
EGFRvIIILow tumor cells in naïve, ER, and DR cells. (D). DAPI-stained metaphases of
naïve, ER, and DR cells probed with EGFR (red) and chromosome 7 centromere probes
(CEP7, green) with abundant EGFR+ extrachromosomal DNA elements in naïve and DR
GBM cells. No extrachromosomal EGFR+ DNA elements were detected in any of the ER
metaphase spreads. The white arrow shows EGFR+ HSR-like staining of a marker
chromosome lacking centromere 7. One such DNA element was found in metaphases from
each ER GBM cell analyzed. They were also detected in some naïve and drug-removed
metaphases. (E) Map of EGFR gene between exon 1 and intron 8. (F) Southern blot analysis
shows binding of EGFR probe (red line) to low-molecular-weight DNA, which is lost during
resistance and reemerges with drug withdrawal. Normal genomic DNA is used as control for
EGFR probe. (G) PCR using primers spanning each of the 17 Bam H1 restriction sites from
5′ of exon 1 through intron 8 (see supplementary materials) was used to identify EGFRvIII
or wild-type EGFR. Primer pairs 13/17 and 14/17 span regions that are 32 kb apart in wild-
type EGFR but only slightly more than 4 kb in EGFRvIII. Primer pairs 13/17 and 14/17
cannot amplify wild-type EGFR but result in amplification of EGFRvIII from low-
molecular-weight DNA of naïve and drug-removed GBM39 cells. No EGFRvIII was
detected in erlotinib-resistant GBM39 cells. Primers 15 and 16 are both deleted in EGFRvIII
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but maintained in wild-type EGFR. Primer pair 16/17 yields a 3.3-kb wild-type EGFR band
in normal control DNA. Representative images of primer pairs 16/17 and 13/17 are shown.
(H and I) Sequencing of the cloned fragments reveals identical intronic breakpoints
associated with a 27,785–base pair deletion of exon 3 to 7 sequences and resulting in
EGFRvIII transcript and protein in treatment-naïve and drug-removed GBM39 cells.
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Fig. 4. Loss of EGFR extrachromosomal DNA elements in GBM patient samples treated with
EGFR TKI
(A) Quantitative PCR analysis of EGFRvIII extrachromosomal DNA in three GBM patient-
derived neurosphere lines. Erlotinib resistance for GBM6 and HK296 was established by
continuous erlotinib treatment (1 μM) for 30 days. DR for GBM6 and HK296 was
established after removing erlotinib from ER cultures for 3 days. Conditions for GBM39
were described above. Values are mean ± SEM from n > 9 replicates. *P < 0.0001 from
unpaired t test. (B) Representative images (left) and quantification (right) from dual-
colorFISH(CEP7,green;EGFR, red) performed on pre/post matched pairs of GBM tissue
sections from n = 2 patients treated with lapatinib for 10 days (patients #2 and #3 from Fig.
1J). Nuclei were counterstained with DAPI. Values are mean ± SD. *P < 0.005 from
unpaired t test. (C) Representative images (left) and quantification (right) from dual-color
FISH (CEP7, green; EGFR, red) performed on pre/post matched pairs of GBM tissue
sections from n = 4 EGFRvIII-positive patients treated with radiation and concomitant
chemotherapy using standard dosing of temozolomide. Nuclei were counterstained with
DAPI. Values are mean ± SD.
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